We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Device News
Trending
Commercial Operations
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Webinar Recordings
Resources
Form 483s Database
FDA Approved Drugs
CenterWatch
WCG Clinical
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Jonathan Matrisciano
Jonathan Matrisciano
Products
PRODUCTS
Medical Technical Gases, Inc.
Jonathan Matrisciano
Price:
$117.00
View
Berkshire Sterile Manufacturing, Inc.
Jonathan Matrisciano
Price:
$117.00
View
Northern VA Compounders, PLLC
Jonathan Matrisciano
and
Daniel J. Min
Price:
$117.00
View
Amneal Pharmaceuticals, LLC
Jonathan Matrisciano
and
Daniel L. Zheng
Price:
$117.00
View
Johnson Memorial Cancer Center
Jonathan Matrisciano
Price:
$117.00
View
Hopkinton Drug, Inc.
Erik W. Koester
,
Jonathan Matrisciano
, and
Daniel L. Zheng
Price:
$117.00
View
8046255 Canada, Inc. dba Viatrexx
Jonathan Matrisciano
Price:
$117.00
View
Roger Williams Medical Center
Jonathan Matrisciano
and
Jonah S. Ufferfilge
Price:
$117.00
View
New England Home Therapies, Inc.
Jonathan Matrisciano
and
Edmund F. Mrak
Price:
$117.00
View
Autumn Harp, Inc.
Jonathan Matrisciano
Price:
$117.00
View
View All Products by Jonathan Matrisciano
Upcoming Events
21
Oct
MAGI@home Clinical Research Conference 2024
Featured Products
From QSR to QMSR: Meeting FDA’s New Requirements
FDA Oversight of Laboratory-Developed Tests — The Impact of the Final Rule
Featured Stories
Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says
Three Device Areas Added to CDRH’s Device-Advancing TAP Program
Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand
Draft Guidance Covers Using URRAs in Combo Product Applications
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
